Abbott to sell Cholestech's GDX system globally:
This article was originally published in Clinica
Executive Summary
Abbott is to distribute globally Cholestech's GDX system for the determination of glycated haemoglobin, an indicator of long-term glycaemic control. Abbott will also offer the Cholestech LDX system with the two products representing "a full complement of products for immediate risk assessment and therapeutic monitoring of heart disease and diabetes", according the Timothy Still, Hayward, California-based Cholestech's vice-president of sales and marketing.
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.